论文部分内容阅读
目的探讨前列地尔注射液联合缬沙坦治疗早前糖尿病肾病的疗效及安全性分析。方法选取2015年4月—2016年5月本院收治的早前糖尿病肾病80例临床资料完整的患者,按随机数字法分为观察组和对照组各40例。2组均给予常规降糖治疗,对照组在此基础上口服缬沙坦80 mg,1次/d;观察组在对照组的基础上静脉滴注前列地尔注射液10μg,1次/d,两组连续用药4周。观察比较两组的临床疗效、微量白蛋白尿排泄率(UAER)、血清肌酐(Cr)、尿素氮(BUN)等变化情况及不良反应情况。结果治疗后,观察组总有效率95%优于对照组(77.5%),差异有统计学意义(P<0.05);2组UAER、Cr、BUN均有所降低,观察组下降幅度大于对照组,差异有统计学意义(P<0.05);2组均未发现严重不良反应,且观察组不良反应发生率低于对照组,但差异无统计学意义(P>0.05)。结论前列地尔注射液联合缬沙坦治疗早前糖尿病肾病能有效改善患者肾功能,效果显著,有较高安全性。
Objective To investigate the efficacy and safety of alprostadil injection combined with valsartan in the treatment of previous diabetic nephropathy. Methods From April 2015 to May 2016, 80 patients with previous diabetic nephropathy who were admitted to our hospital were selected and divided into observation group (40 cases) and control group (40 cases) according to random number method. Both groups were given routine hypoglycemic treatment, the control group on the basis of oral valsartan 80 mg, 1 / d; the observation group in the control group based on the intravenous infusion of alprostadil 10μg, 1 / d, Two groups of continuous medication for 4 weeks. The clinical efficacy, urinary albumin excretion rate (UAER), serum creatinine (Cr), blood urea nitrogen (BUN) and other adverse reactions were compared between the two groups. Results After treatment, the total effective rate in the observation group was 95% better than that in the control group (77.5%), the difference was statistically significant (P <0.05); the UAER, Cr and BUN decreased in both groups, (P <0.05). No serious adverse reactions were found in the two groups, and the incidence of adverse reactions in the observation group was lower than that in the control group, but the difference was not statistically significant (P> 0.05). Conclusion Alprostadil injection combined with valsartan in the treatment of early diabetic nephropathy can effectively improve renal function in patients with significant effect and high safety.